Stentys appoints Lesh as director
Stentys’ board of directors has appointed Michael Lesh, MD, as a director, effective immediately.
Since 2004, Lesh has served as chairman and CEO of Evera Medical, one of four companies he has founded, the company said. His first venture, Atrionix, a developer of an ultrasound ablation catheter for atrial fibrillation, was acquired by Johnson & Johnson.
He established Mitralife, a developer of a catheter-based treatment for mitral valve disease and coronary heart failure, which was acquired by ev3. Lesh also founded Appriva Medical, developer of PLAATO, a percutaneous transcatheter device for preventing stroke, which was acquired by ev3.
The Paris-based Stentys is developing a next-generation drug-eluting stent for treatment of blocked coronary artery bifurcations.
Since 2004, Lesh has served as chairman and CEO of Evera Medical, one of four companies he has founded, the company said. His first venture, Atrionix, a developer of an ultrasound ablation catheter for atrial fibrillation, was acquired by Johnson & Johnson.
He established Mitralife, a developer of a catheter-based treatment for mitral valve disease and coronary heart failure, which was acquired by ev3. Lesh also founded Appriva Medical, developer of PLAATO, a percutaneous transcatheter device for preventing stroke, which was acquired by ev3.
The Paris-based Stentys is developing a next-generation drug-eluting stent for treatment of blocked coronary artery bifurcations.